Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Transformation of Multiple Myeloma into Extramedullary Myeloma or Plasma Cell...
share announcement

Transformation of Multiple Myeloma into Extramedullary Myeloma or Plasma Cell Leukemia

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (30 June 2022) | Viewed by 4797

Special Issue Editor

Dr. Sabina Ševčíková

E-Mail Website
Guest Editor
Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
Interests: monoclonal gammopathies and their molecular nature

Special Issue Information

Dear Colleagues,

Multiple myeloma is the second most common hematological malignancy. It is characterized by malignant plasma cell infiltration of the bone marrow. Unfortunately, a subclone of these plasma cells may also migrate out of the bone marrow losing its dependence on the bone marrow microenvironment. Thus, multiple myeloma may transform into extramedullary myeloma (EM) (plasma cells infiltrate soft tissues, sometimes forming tumors) or plasma cell leukemia (PCL) (plasma cells migrate into peripheral blood). Both EM and PCL have unfavorable clinical outcomes.

This Special Issue “Transformation of Multiple Myeloma into Extramedullary Myeloma or Plasma Cell Leukemia” aims to clarify the pathogenesis of EM and/or PCL, biomarkers of these diseases, early diagnosis options, translational research, and treatment options. We welcome original basic, translational, and molecular biology-based clinical research articles, as well as review articles, leading to an improvement in our understanding of both EM and PCL.

Dr. Sabina Ševčíková
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Extramedullary myeloma
  • Plasma cell leukemia
  • Biomarkers
  • Therapy
  • Early diagnosis

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 1261 KiB  
Article
Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
by Martin Stork, Sabina Sevcikova, Tomas Jelinek, Jiri Minarik, Jakub Radocha, Tomas Pika, Lenka Pospisilova, Ivan Spicka, Jan Straub, Petr Pavlicek, Alexandra Jungova, Zdenka Knechtova, Viera Sandecka, Vladimir Maisnar, Roman Hajek and Ludek Pour
Biomedicines 2022, 10(10), 2535; https://doi.org/10.3390/biomedicines10102535 - 11 Oct 2022
Cited by 2 | Viewed by 1502
Abstract
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define [...] Read more.
In multiple myeloma (MM), malignant plasma cells infiltrate the bone marrow. In some cases, plasma cells migrate out of the bone marrow creating either para-skeletal plasmacytomas (PS) or infiltrating soft tissues as extramedullary plasmacytomas (EMD). The aim of this study was to define risk groups in newly diagnosed MM (NDMM) patients with PS and EMD plasmacytomas. In total, 523 NDMM patients with PS plasmacytomas and 196 NDMM patients with EMD plasmacytomas were diagnosed in the Czech Republic between 2004 and 2021 using modern imaging methods. Patients’ data were analyzed from the Registry of Monoclonal Gammopathies of the Czech Myeloma Group. In NDMM patients with PS plasmacytomas, we found a subgroup with <5% of bone-marrow plasma cells to have the best prognosis (mPFS: 58.3 months (95% CI: 33.0–NA); mOS: not reached). The subgroup with >5% of bone-marrow plasma cells and ≥3 plasmacytomas had the worst prognosis (mPFS: 19.3 months (95% CI: 13.4–28.8), p < 0.001; mOS: 27.9 months (95% CI: 19.3–67.8), p < 0.001). Our results show association between tumor burden and prognosis of NDMM patients with plasmacytomas. In the case of PS plasmacytomas, NDMM patients with low BM PC infiltration have an excellent prognosis. Full article
(This article belongs to the Special Issue Transformation of Multiple Myeloma into Extramedullary Myeloma or Plasma Cell Leukemia)
►▼ Show Figures

Figure 1

11 pages, 1186 KiB  
Article
LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients
by Romana Bútová, Petra Vychytilová-Faltejsková, Jana Gregorová, Lenka Radová, Martina Almáši, Renata Bezděková, Lucie Brožová, Jiří Jarkovský, Zdeňka Knechtová, Martin Štork, Luděk Pour and Sabina Ševčíková
Biomedicines 2021, 9(11), 1637; https://doi.org/10.3390/biomedicines9111637 - 08 Nov 2021
Cited by 5 | Viewed by 2001
Abstract
Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, [...] Read more.
Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression. Full article
(This article belongs to the Special Issue Transformation of Multiple Myeloma into Extramedullary Myeloma or Plasma Cell Leukemia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop